CurrentCapital BluecrossPolicy AHS - G2113 - Oral Cancer Screening and Testing, 1

Oral Cancer Screening and Testing

Coverage policy for diagnostic testing related to oral and oropharyngeal cancer, including HPV and salivary/blood biomarker tests; applies to Capital Bluecross members as implemented via Avalon Health Services policy language.

Policy Summary

PayerCapital Bluecross

PolicyOral Cancer Screening and Testing

Policy CodePolicy AHS - G2113 - Oral Cancer Screening and Testing, 1

Change TypeNo material change

Effective Date06/16/2015

Next Review DateN/A

Key ActionPerform p16 immunohistochemistry or high-risk HPV E6/E7 mRNA testing to establish HPV tumor status for oropharyngeal squamous cell carcinoma or metastatic SCC of unknown primary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

59,660US diagnoses (2024)

12,770US deaths (2024)

Recommendedp16 IHC stance

0429UListed HPV swab code

CLIA

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Covered testing

Covered when ALL of the following are met

HPV tumor status testing in oropharyngeal SCC or metastatic SCC of unknown primary: Testing for high-risk HPV to establish tumor status using either E6/E7 mRNA expression testing OR p16 immunohistochemistry meets coverage criteria.

Per policy statement; aligns with CAP, NCCN, and ASCO recommendations that p16 IHC is an accepted surrogate for HPV status in oropharyngeal cancers.

Not covered screening tests

Not covered for screening/diagnosis when used in the following ways

Non-covered tests for screening/detection/diagnosis of oral cancer: Use of salivary biomarker testing (peptides/proteins, nucleic acids, metabolites), HPV genotyping tests (e.g., OraRisk®), gene expression profiling, panels combining genetic and nongenetic biomarkers (e.g., mRNA CancerDetect™), and detection of HPV from an oropharyngeal swab (e.g., OmniPathology Oropharyngeal HPV PCR Test) DOES NOT MEET COVERAGE CRITERIA.

Policy cites lack of sufficient published evidence and guideline recommendations against routine screening of asymptomatic individuals.

HPV testing recommendations

Covered/Recommended testing when criteria below apply

Routine p16 IHC for oropharyngeal cancers: Perform p16 immunohistochemistry on oropharyngeal tissue specimens as a surrogate marker for high-risk HPV in patients diagnosed with oropharyngeal squamous cell carcinoma.

Recommended by NCCN, CAP, ASCO, and European guidance as the initial surrogate test for HPV status.

When to perform HPV-specific testing in addition to p16: Perform HPV-specific (E6/E7 mRNA or other HR-HPV specific) testing in selected scenarios: geographic regions with low prevalence of HR-HPV-associated OPSCC; when p16 immunostaining is equivocal (50%–70% staining or extensive but weak); when there is discrepancy between p16 staining and tumor morphology; for large multisite tumors overlapping the oropharynx; when specimens are from non-tonsillar/non-base-of-tongue oropharyngeal sites; when required by clinical trials; and for metastatic SCC of unknown primary as recommended.50%-70% staining or extensive but weak staining (equivocal p16)

CAP specifically lists these scenarios; ASCO and European guidelines support p16 with conditional additional testing as indicated.

Routine screening of asymptomatic individuals using oropharyngeal swab HPV DNA tests and other saliva- or genotype-based panels DOES NOT MEET COVERAGE CRITERIA. Examples explicitly listed include salivary biomarker testing, HPV genotyping assays (e.g., OraRisk®), gene expression profiling, panels combining genetic and nongenetic biomarkers (e.g., mRNA CancerDetect™), and detection of HPV from an oropharyngeal swab (e.g., OmniPathology Oropharyngeal HPV PCR Test). These tests are excluded because current evidence and guideline recommendations do not support routine swab-based or saliva-based screening of asymptomatic individuals for oropharyngeal cancer.

The College of American Pathologists (CAP) advises that routine HR-HPV testing is NOT recommended for non-squamous carcinomas of the head and neck for prognostic purposes (strong recommendation, evidence level high). CAP’s guidance therefore limits routine HR-HPV testing to specified squamous cell carcinoma contexts and recommends against its routine use for prognostication in non-squamous histologies.

Tests including salivary biomarker panels, HPV genotyping assays (for example, OraRisk®), gene expression profiling, and combined genetic/nongenetic panels (for example, mRNA CancerDetect™) are designated as not meeting coverage criteria when used to screen, detect, or diagnose oral cancer. The policy lists these methods specifically and cites insufficient published evidence that they are required and beneficial for diagnosis or treatment, so they are considered not medically necessary for routine diagnostic or screening use.

Adjunctive screening aids based on autofluorescence or tissue reflectance are not included in the NCCN head and neck cancer management recommendations and therefore are not supported as standard management tools. The NCCN guidelines do not mention these adjunctive optical technologies as endorsed approaches for screening or clinical decision-making in head and neck cancers.

Coding and Procedure Codes

Policy identifier / referenced procedure codemixed

G2113

Oral Cancer Screening and Testing (policy header code shown)

Applicable CPT/HCPCS Procedure Codesmixed

82397	Chemiluminescent assay.
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
0429U	Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) — Omnipathology Oropharyngeal HPV PCR Test.

p16 equivocal staining

Equivocal p16 IHC definition50%-70% nuclear and cytoplasmic staining or extensive but weak staining

Clinical implicationEquivocal p16 results should prompt HPV-specific testing per CAP guidance (e.g., E6/E7 mRNA) or reflex testing in outlined scenarios

Context of useApplied when interpreting p16 immunohistochemistry on oropharyngeal tissue specimens

Provider Actions and Documentation

Billing Rule

Procedure codes and LDT regulatory note

Procedure codes relevant to HPV testing of oropharyngeal / head and neck specimens are listed for billing reference. Laboratory-developed tests (LDTs) are commonly used for HPV assays; these are regulated under CLIA/CMS as high-complexity tests and are not FDA-cleared/approved. FDA clearance is not required for clinical use of LDTs at this time.

Covered/proprietary and example procedure codes: 82397 (chemiluminescent assay); 88342 (IHC, initial single antibody stain); 88341 (IHC, each additional single antibody stain); 0429U (HPV, oropharyngeal swab — OmniPathology Oropharyngeal HPV PCR Test).
LDT regulatory note: Laboratory-developed tests must be validated and performed in-house and are regulated by CMS under CLIA as high-complexity tests. LDTs are not FDA-approved/cleared, though FDA clearance is not currently required for clinical use.

Documentation Required

Background

Oral cancer is predominantly epithelial in origin, with the majority of tumors being oral squamous cell carcinoma (SCC). These cancers arise in the oral cavity and oropharynx and may be preceded by potentially malignant disorders. For oropharyngeal SCC, human papillomavirus (HPV) is an established etiologic contributor and testing to establish HPV tumor status is clinically relevant for management in specific settings. CAP and other guideline bodies recommend the use of p16 immunohistochemistry as a surrogate marker for HR-HPV in oropharyngeal tissue specimens and endorse HPV-specific testing (E6/E7 mRNA or other validated assays) in defined scenarios such as equivocal p16 staining, geographic low-prevalence regions, discrepant morphology, non-tonsillar sites, large multisite tumors, or when required by clinical trials. Routine population screening to detect oral HPV infection using swab or saliva tests is not supported.

Definitions and Acronyms

Oral cancer — definition and anatomic boundaries

DefinitionCancer occurring in the oral cavity between the vermilion border of the lips and the junction of the hard and soft palates or the posterior one third of the tongue

Most common histologySquamous cell carcinoma is the most common type of oral cancer

Anatomic boundaries (key points)Includes vermilion border of lips to hard/soft palate junction; includes posterior one-third of tongue

Acronyms relevant to testing

HPVHuman papillomavirus

HR-HPVHigh-risk human papillomavirus

IHC